MYB and adenoid cystic carcinoma: For adenoid cystic carcinoma, multiple retrospective institutional series comprising aggregate numbers exceeding 200 cases, combined with well-characterized MYB/MYBL1 rearrangements and long-term outcome data, provide a robust evidence base [63,64,65,66,67,68,69,70,71,72,73].